| |
| |
|
| Insider
Information: |
Yale Catriona |
| Relationship: |
|
| City: |
South San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
77,692 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
77,692 |
|
|
| Total
Value |
$0 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Akero Therapeutics, Inc. |
AKRO |
|
2024-03-13 |
77,692 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AKRO |
Akero Therapeutics, Inc. |
Chief Development Officer |
• – – |
2024-03-13 |
4 |
S |
$28.33 |
$20,483 |
D/D |
(723) |
77,692 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Chief Development Officer |
• – – |
2024-03-04 |
4 |
AS |
$35.49 |
$732,727 |
D/D |
(20,646) |
78,415 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Chief Development Officer |
• – – |
2024-03-04 |
4 |
OE |
$6.36 |
$288,124 |
D/D |
20,646 |
99,061 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Chief Development Officer |
• – – |
2023-12-14 |
4 |
S |
$20.76 |
$12,394 |
D/D |
(597) |
77,910 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Chief Development Officer |
• – – |
2023-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
32,497 |
78,507 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Chief Development Officer |
• – – |
2023-09-21 |
4 |
AS |
$47.85 |
$240,356 |
D/D |
(5,000) |
46,010 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Chief Development Officer |
• – – |
2023-09-21 |
4 |
OE |
$6.36 |
$31,800 |
D/D |
5,000 |
51,010 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Chief Development Officer |
• – – |
2023-09-13 |
4 |
AS |
$50.34 |
$31,060 |
D/D |
(617) |
46,010 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Chief Development Officer |
• – – |
2023-08-28 |
4 |
AS |
$49.92 |
$287,191 |
D/D |
(5,745) |
46,627 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Chief Development Officer |
• – – |
2023-08-28 |
4 |
OE |
$6.36 |
$36,538 |
D/D |
5,745 |
52,372 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Chief Development Officer |
• – – |
2023-06-23 |
4 |
S |
$50.73 |
$558,360 |
D/D |
(11,000) |
46,627 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Chief Development Officer |
• – – |
2023-06-22 |
4 |
S |
$52.18 |
$573,935 |
D/D |
(11,000) |
57,627 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Chief Development Officer |
• – – |
2023-06-21 |
4 |
S |
$52.26 |
$593,095 |
D/D |
(11,349) |
68,627 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Chief Development Officer |
• – – |
2023-06-13 |
4 |
AS |
$55.16 |
$32,600 |
D/D |
(591) |
79,976 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Chief Development Officer |
• – – |
2023-03-10 |
4 |
D |
$43.46 |
$30,465 |
D/D |
(701) |
80,567 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Chief Development Officer |
• – – |
2023-01-13 |
4 |
AS |
$49.12 |
$252,651 |
D/D |
(5,000) |
81,268 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Chief Development Officer |
• – – |
2022-12-12 |
4 |
AS |
$43.18 |
$216,137 |
D/D |
(5,000) |
86,268 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Chief Development Officer |
• – – |
2022-12-09 |
4 |
A |
$0.00 |
$0 |
D/D |
19,195 |
91,268 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Chief Development Officer |
• – – |
2022-11-10 |
4 |
AS |
$39.41 |
$197,105 |
D/D |
(5,000) |
72,073 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Chief Development Officer |
• – – |
2022-10-10 |
4 |
AS |
$37.99 |
$189,950 |
D/D |
(5,000) |
77,073 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Chief Development Officer |
• – – |
2022-09-13 |
4 |
AS |
$27.18 |
$1,099,228 |
D/D |
(40,000) |
82,073 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Chief Development Officer |
• – – |
2022-06-30 |
4 |
A |
$8.03 |
$9,251 |
D/D |
1,152 |
122,073 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Chief Development Officer |
• – – |
2021-10-15 |
4 |
AS |
$21.58 |
$269,826 |
D/D |
(12,500) |
120,921 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Chief Development Officer |
• – – |
2021-09-15 |
4 |
AS |
$24.57 |
$308,605 |
D/D |
(12,500) |
133,421 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Chief Development Officer |
• – – |
2021-08-16 |
4 |
AS |
$18.79 |
$187,900 |
D/D |
(10,000) |
145,921 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
